- $192.28m
- $125.69m
- $129.42m
Chromadex Corp expected to post breakeven results a share - Earnings Preview
Brief: Chromadex Appoints Ozan Pamir As Chief Financial Officer
Brief: ChromaDex Says Wells Pharma To Distribute Niagen IV And Injections To 14 New Clinics
Brief: ChromaDex Secures US Patent for the Composition of Matter of Salt Forms of NMNH
Chromadex Corp reports results for the quarter ended in June - Earnings Summary
Chromadex Corp expected to post a loss of 2 cents a share - Earnings Preview
Brief: ChromaDex Corp Appoints James Lee Interim CFO
Brief: ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen Will Debut at Leading Wellness Clinics in August
Brief: Chromadex Corp CFO Brianna Gerber Resigns
Brief: Chromadex Says Results From Phase II Clinical Study Show Promising Effects Of NR Supplementation For People With Peripheral Artery Disease
U.S. STOCKS ON THE MOVE-Vail Resorts, Celanese, Graham
ChromaDex Corp rises on orphan drug tag to develop treatment for genetic disease
Brief: ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
Chromadex Corp reports results for the quarter ended in March - Earnings Summary
Chromadex Corp expected to post a loss of 2 cents a share - Earnings Preview
Brief: Chromadex Corp Ingredient Partnership With Nestlé Health Science Brand Solgar
Chromadex Corp reports results for the quarter ended in December - Earnings Summary
Brief: Chromadex Entered Into An Amendment To Business Financing Agreement On Dec. 8
Brief: ChromaDex Corporation Q3 EPS USD -0.01